Command Palette

Search for a command to run...

Clinical Trials · NCT05110794

A Multiple-Dose Study of LY3502970 in Healthy Participants

CompletedPhase 1Orforglipron (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
34
Start date
Nov 2021
Locations
1 site, Singapore
Primary endpoint
PK: Maximum Observed Concentration (Cmax) of LY3502970
View Orforglipron compound reference